Omnicell Unveils Groundbreaking Robotic Compounding Technology in Winter 2022 Release

Dennis Wright
Senior Director, Product Marketing, Omnicell

For more than 15 years, IV robotics has proven efficacy in safe and efficient sterile compounding, but market adoption has been limited.

We needed to go back to the drawing board. So, we started with our customers, conducting over 100 interviews to understand their concerns. We also drew on over 10 years of automation data, which was represented by over 8 million IV preparations that have run through automation technology. The team combined the direct customer feedback with the large dataset to identify two improvement themes: throughput and reliability.

Our engineering team scoured through design ideas and broke down all the compounded activities into individual tasks. We put a lot of time, effort, and money into researching new ideas, performing time studies, developing prototypes, field testing them, and iterating on designs to find the right answers. By the numbers, we:

• Performed more than 1 million test cycles on subsystems and entire systems
• Tested and implemented over 3,000 new parts
• Developed and deployed over 500,000 lines of new software

The result? A new era of IV robotics in the IVX Station, new technology introduced as part of Omnicell's Winter 2022 Release. This totally reimagined robot features:

• Innovative design that delivers three times faster throughput than previous technology*
• Solid-core structure that eliminates the need for repeated recalibration, which is the number one cause of downtime
• Compact footprint – comparable to a 4-foot hood

The IVX Station was designed to help facilitate regulatory compliance. It includes an entirely automated compounding process in an ISO Class 5 environment as well as temperature, humidity, and continuous particle monitoring. It was also made with safety in mind, incorporating advanced vision systems, gravimetric verification, auto-labeling, and automatic application of tamper-evident caps for syringes.

In addition, this new technology supports scalability. You can implement one device or many in a centralized compounding facility. Customers can leverage our cloud-based library of formulations which is continually updated to ensure you have access to the latest approved formulations.

IVX Station is the foundation of Omnicell's IV Compounding Service (IVCS), providing the technology, tools, and experts to automate your sterile compounding process. This comprehensive, as-a-Service solution allows you to enhance safety, gain control of your IV supply chain, and drive cost savings. Current IVCS customers achieve a 70 percent higher monthly throughput on average than those who made a capital purchase.

We're thrilled to introduce the all-new IVX Station. Learn more about how you can achieve smarter, safer, more efficient sterile compounding operations.

The Omnicell Blog is the leading source for pharmacy care, exploring emerging trends, successful best practices, and ideas and insights focused on the digital transformation of pharmacy. Subscribe today.

*Throughput varies depending on the protocol.

Disclaimer
The views and opinions expressed in this blog are those of the authors and do not necessarily reflect the official policy or position of any other agency, organization, employer, or company. Assumptions made in the analysis are not reflective of the position of any entity other than the author(s). These views are always subject to change, revision, and rethinking at any time and may not be held in perpetuity.